Showing 3981-3990 of 7172 results for "".
- Phase 3 Data Evaluating Almirall’s Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Publishedhttps://practicaldermatology.com/news/phase-3-data-evaluating-almiralls-lebrikizumab-in-moderate-to-severe-atopic-dermatitis-published/2461640/Almirall announced the publication of Week 16 and Week 52 results of ADvocate1 and ADvocate2 by the New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD), respectively. ADvocate1 and ADvocate2 are two identical 52-week randomized, double-blind, plac
- Treatment Options to Consider for Pregnant Women Living with Eczema and Psoriasishttps://practicaldermatology.com/news/treatment-options-to-consider-for-pregnant-women-living-with-eczema-and-psoriasis/2461639/Psoriasis and eczema affect men and women differently, with women needing to take extra precautions when considering treatments if they’re planning for pregnancy, according to a news release from the American Academy of Dermatology. At the recent American Academy of Dermatology&rs
- Study: Atopic Asthma/Eczema Linked to Heightened Risk of Osteoarthritishttps://practicaldermatology.com/news/study-atopic-asthmaeczema-linked-to-heightened-risk-of-osteoarthritis/2461635/People with atopic diseases like asthma or eczema may be at heightened risk of osteoarthritis, according to research published online in the Annals of the Rheumatic Diseases. Drugs used to dampen d
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was
- Phase 3 Studies Show Lebrikizumab Effective in Patients With Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/phase-3-studies-show-lebrikizumab-effective-in-patients-with-moderate-to-severe-atopic-dermatitis/2461630/After 16 weeks of treatment, lebrikizumab (Almirall) was effective in adolescents and adults with moderate-to-severe atopic dermatitis, according to two Phase 3 studies. The research was published in the New England Journal of
- EON Robotic Body Contouring Device Receives Additional FDA Clearance for Back and Thighshttps://practicaldermatology.com/news/eon-robotic-body-contouring-device-receives-additional-fda-clearance-for-back-and-thighs/2461629/EON Smarter Body Contouring has received FDA clearance for the back and thighs—the third FDA clearance for EON. The device was previously FDA-cleared for clinical providers to treat patients' full abdomen and flanks. Parent company Dominion Aesthetic Technologies describe
- Game On: Level Ex, GladskinMD Introduce Battle of the Biomehttps://practicaldermatology.com/news/game-on-level-ex-gladskinmd-introduce-battle-of-the-biome/2461618/Level Ex is teaming up with Gladskin to create custom, interactive gaming experiences that educate and train medical professionals on the science of endolysin technology and Gladskin’s new product line. As its first collaboration, the companies created a game called Batt
- Eye on OX40 in AD: Rocatinlimab Performs Well in Two Phase 2 Trialshttps://practicaldermatology.com/news/eye-on-ox40-in-ad-rocatinlimab-performs-well-in-two-phase-2-trials/2461617/OX40 is considered a new potential treatment target in atopic dermatitis (AD), and two new studies of the investigational anti-OX40 monoclonal antibody rocatinlimab may add weight to the evidence. Rocatinlimab inhibits and reduces the number of OX40+ pathogenic T cells responsible
- Guselkumab Shows Greater Treatment Persistence than IL-17s in Both Bio-naïve and Bio-experienced Psoriasis Patientshttps://practicaldermatology.com/news/guselkumab-shows-greater-treatment-persistence-than-il-17s-in-both-bio-naive-and-bio-experienced-psoriasis-patients/2461613/Tremyfa (guselkumab) may beat out other biologics when it comes to patient persistence, and a post-hoc analysis of guselkumab showed improvements in scalp psoriasis and quality-of-life measures at week 48. Research found that bio-experienced and bio-naïve psoria
- Cetaphil Celebrates Sensitive Skin with a Month of Skin Science Educationhttps://practicaldermatology.com/news/cetaphil-celebrates-sensitive-skin-with-a-month-of-skin-science-education/2461610/Cetaphil is ringing in the 2nd Annual Sensitive Skin Awareness initiative globally with a month of skin science education. Activating under the brand's campaign, "We Do Skin. You Do You," the global science effort will arm consumers with guidance on how to i